Anabolic androgenic steroids in the treatment of acquired aplastic anemia.
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced; D045930:Anabolic Agents / Q000009:adverse effects; D000732:Androstanols / Q000627:therapeutic use*; D000741:Anemia, Aplastic / Q000188:drug therapy*; D001792:Blood Platelets / Q000187:drug effects; D004912:Erythrocytes / Q000187:drug effects; D005260:Female; D006801:Humans; D007565:Jaundice / Q000139:chemically induced; D007962:Leukocytes / Q000187:drug effects; D008297:Male; D008696:Methandrostenolone / Q000627:therapeutic use*; D008710:Methenolone / Q000627:therapeutic use*; D008875:Middle Aged; D010110:Oxymetholone / Q000627:therapeutic use*; D011379:Prognosis; D012156:Reticulocytes / Q000187:drug effects; D014770:Virilism / Q000139:chemically induced
D000305:Adrenal Cortex Hormones; D045930:Anabolic Agents; D000732:Androstanols; D008710:Methenolone; D008696:Methandrostenolone; D010110:Oxymetholone